MedTrace Logo

EWO1 in Persistent Allergic Rhinitis Patients

NCT00153595 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2007-07-25

No results posted yet for this study

Summary

The aim of this double-blind, randomized, parallel group, placebo-controlled study is to assess the efficacy and safety of EWO1 in patients with moderate to severe perennial allergic rhinitis (AR).

Conditions

  • Rhinitis, Allergic, Perennial

Interventions

DRUG

EWO1

Sponsors & Collaborators

  • China Medical University Hospital

    lead OTHER

Principal Investigators

  • Min-Chien Yu, Ph.D. · China Medical University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00153595 on ClinicalTrials.gov